PolyPid Ltd.(PYPD)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
PYPD Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for PolyPid Ltd. (PYPD), a Healthcare sector company. PYPD is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (FY 2025), PolyPid Ltd. reports net income of $-34.2M, free cash flow of $-28.1M. Top institutional holders of PYPD by reported 13-F value include AIGH Capital Management, Rosalind Advisors, DAFNA Capital Management, based on the most recent SEC filings. PYPD trades on the Nasdaq exchange and files with the SEC under CIK 1611842. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PYPD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for PolyPid Ltd. directly from SEC EDGAR.
Net Income
FY 2025
$-34.2M
Free Cash Flow
FY 2025
$-28.1M
D/E Ratio
FY 2025
0.09
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProNet Income
-17.7% YoYOperating Income
-17.6% YoYEPS (Diluted)
-57.4% YoYTotal Assets
-11.6% YoYTotal Debt
-86.7% YoYOp. Cash Flow
-26.9% YoYFree Cash Flow
-27.5% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Net Income | $-34.2M -17.7% | $-29.0M -21.6% | $-23.9M +39.7% | $-39.6M +7.1% | $-42.6M -15.5% | $-36.9M |
| Operating Income | $-33.0M -17.6% | $-28.0M -22.6% | $-22.9M +41.2% | $-38.9M +9.9% | $-43.1M -64.2% | $-26.3M |
| EPS (Diluted) | $2.09 -57.4% | $4.91 -13.0% | $5.64 -72.3% | $20.36 -10.5% | $22.76 +1423.9% | $1.49 |
| Total Assets | $22.3M -11.6% | $25.2M +64.1% | $15.4M -40.8% | $26.0M -41.3% | $44.2M -41.7% | $75.8M |
| Total Debt | $988.0K -86.7% | $7.4M -28.5% | $10.4M -18.7% | $12.8M | — | — |
| Operating Cash Flow | $-27.9M -26.9% | $-22.0M -27.4% | $-17.2M +49.8% | $-34.3M -6.0% | $-32.4M -50.0% | $-21.6M |
| Free Cash Flow | $-28.1M -27.5% | $-22.0M -26.4% | $-17.4M +51.7% | $-36.1M -3.0% | $-35.0M -56.6% | $-22.4M |
Get alerted when PYPD's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for PolyPid Ltd. including:
Top Institutional Holders of PYPD
AIGH Capital Management LLC
$7.6M1,504,741 shRosalind Advisors, Inc.
$2.0M389,455 shDAFNA Capital Management LLC
$1.1M207,900 shMORGAN STANLEY
$625.5K123,136 shRENAISSANCE TECHNOLOGIES LLC
$592.4K116,619 shMARSHALL WACE, LLP
$584.3K115,014 shADAR1 Capital Management, LLC
$528.1K103,950 shSYMMETRY PEAK MANAGEMENT LLC
$512.5K100,881 shJ. Goldman & Co LP
$503.9K99,183 shJANE STREET GROUP, LLC
$422.3K83,126 sh
| Fund | Value | Shares |
|---|---|---|
| AIGH Capital Management LLC | $7.6M | 1,504,741 |
| Rosalind Advisors, Inc. | $2.0M | 389,455 |
| DAFNA Capital Management LLC | $1.1M | 207,900 |
| MORGAN STANLEY | $625.5K | 123,136 |
| RENAISSANCE TECHNOLOGIES LLC | $592.4K | 116,619 |
| MARSHALL WACE, LLP | $584.3K | 115,014 |
| ADAR1 Capital Management, LLC | $528.1K | 103,950 |
| SYMMETRY PEAK MANAGEMENT LLC | $512.5K | 100,881 |
| J. Goldman & Co LP | $503.9K | 99,183 |
| JANE STREET GROUP, LLC | $422.3K | 83,126 |
More Healthcare Companies
View all Healthcare →Put PYPD on your watchlist
Track score changes the day PolyPid Ltd. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is PYPD a good stock to buy?
13F Pro's AI-powered analysis of PolyPid Ltd. (PYPD) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PYPD are available on the PYPD stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. PYPD is classified as a small company.
Which hedge funds own PYPD?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PYPD. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of PolyPid Ltd.'s investment landscape.